

CONTENTS

<i>Preface</i>	v
<i>Contributors</i>	xi
PART I: DIAGNOSIS, CLASSIFICATION, AND PROGNOSIS	
1 Classification of Acute Leukemias: <i>Perspective 1</i>	3
<i>Wolf-Dieter Ludwig, Torsten Haferlach, and Claudia Schoch</i>	
2 Classification of Acute Leukemias: <i>Perspective 2</i>	43
<i>Frederick G. Behm</i>	
PART II: CHEMOTHERAPEUTIC STRATEGIES	
A. Infant Leukemias	
3 Biology and Treatment of Infant Leukemias: <i>Perspective 1</i>	61
<i>Rob Pieters</i>	
4 Biology and Treatment of Acute Leukemias in Infants: <i>Perspective 2</i>	75
<i>Gregory H. Reaman</i>	
B. Childhood Acute Lymphoblastic Leukemia	
5 Treatment of Childhood Acute Lymphoblastic Leukemia	87
<i>Martin Schrappe and Martin Stanulla</i>	
6 Treatment of Childhood Acute Lymphoblastic Leukemia: <i>The Dana-Farber Cancer Institute ALL Consortium Perspective</i>	105
<i>Lewis B. Silverman and Stephen E. Sallan</i>	
C. Acute Lymphoblastic Leukemia in Adolescents and Young Adults	
7 Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults: <i>Lessons Learned and Future Directions</i>	113
<i>Sima Jeha and Hagop M. Kantarjian</i>	
8 Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia: <i>Children's Cancer Group Trials</i>	121
<i>James Nachman</i>	
D. Acute Lymphoblastic Leukemia in Adults	
9 Treatment of Adult Acute Lymphoblastic Leukemia: <i>Perspective 1</i>	131
<i>Spero R. Cataland and Richard A. Larson</i>	
10 Treatment of Adult Acute Lymphoblastic Leukemia: <i>Perspective 2</i>	143
<i>Dieter Hoelzer and Nicola Gökbüget</i>	
E. Central Nervous System Therapy for Acute Lymphoblastic Leukemia	
11 Central Nervous System–Directed Therapy for Acute Lymphoblastic Leukemia	161
<i>Judith M. Chessells</i>	
12 Diagnosis, Prophylaxis, and Treatment of Central Nervous System Involvement in Acute Lymphoblastic Leukemia	173
<i>Anjo J. P. Veerman</i>	
F. Relapsed Acute Lymphoblastic Leukemia	
13 Treatment of Relapsed Acute Lymphoblastic Leukemia: <i>Perspective 1</i>	183
<i>Helmut Gadner, Georg Mann, and Christina Peters</i>	
14 Treatment of Relapsed Acute Lymphoblastic Leukemia: <i>Perspective 2</i>	199
<i>Günter Henze and Arend von Stackelberg</i>	

	G. B-Cell Acute Lymphoblastic Leukemia	
15	Treatment of B-Cell Acute Lymphoblastic Leukemia: <i>Perspective 1</i> <i>Catherine Patte</i>	223
16	Treatment of B-Cell Acute Lymphoblastic Leukemia: <i>Perspective 2</i> <i>John T. Sandlund</i>	229
	H. Acute Myeloid Leukemia in Children	
17	Treatment of Acute Myeloid Leukemia in Children <i>Ursula Creutzig</i>	237
18	Treatment of Childhood Acute Myeloid Leukemia <i>David M. Loeb and Robert J. Arceci</i>	255
	I. Acute Myeloid Leukemia in Adults	
19	Therapy of Acute Myeloid Leukemia in Adults <i>Bob Löwenberg</i>	270
20	Treatment of Adult Acute Myelogenous Leukemia <i>Ricardo T. Spielberger and Stephen J. Forman</i>	279
	J. Acute Promyelocytic Leukemia	
21	Acute Promyelocytic Leukemia: <i>Perspective 1</i> <i>Zhu Chen and Zhen-Yi Wang</i>	291
22	Acute Promyelocytic Leukemia: <i>Perspective 2</i> <i>Francesco Lo Coco, Giuseppe Avvisati, and Franco Mandelli</i>	311
	K. Childhood Leukemias in Underprivileged Countries	
23	Treatment of Childhood Leukemias in Underprivileged Countries <i>Bharat Agarwal and Rashmi Dalvi</i>	321
24	How to Confront the Problem of Treatment of Childhood Leukemias in Underprivileged Populations <i>Giuseppe Masera and Andrea Biondi</i>	331
	PART III: ANTILEUKEMIC DRUGS	
	A. High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia	
25	Rationale for High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia <i>Timothy L. Brenner and William E. Evans</i>	339
26	Role of Methotrexate in the Treatment of Acute Lymphoblastic Leukemia <i>Bruce M. Camitta and Barton A. Kamen</i>	357
	B. Asparaginase	
27	Asparaginase <i>Barbara L. Asselin and Joanne Kurtzberg</i>	365
28	Asparaginase Treatment <i>Carmelo Rizzari</i>	381
	C. Antipurines in Childhood Acute Lymphoblastic Leukemia	
29	Antipurines in Childhood Acute Lymphoblastic Leukemia <i>Paul S. Gaynon and Peter C. Adamson</i>	395
30	Antipurines <i>Lynne Lennard and John S. Lilleyman</i>	405
	D. Epipodophyllotoxins	
31	Etoposide in Acute Leukemias: <i>Therapeutic and Pharmacokinetic Considerations</i> <i>Mary V. Relling</i>	421
32	Etoposide and Teniposide: <i>Clinical Applications with a Focus on Leukemia</i> <i>Malcolm A. Smith</i>	429

PART IV: HEMATOPOIETIC STEM CELL TRANSPLANTATION

- 33 Hematopoietic Stem Cell Transplantation: *Perspective 1* **441**
Frederick R. Appelbaum
- 34 Hematopoietic Stem Cell Transplantation: *Perspective 2* **449**
Vilmarie Rodriguez and Helen E. Heslop

PART V: BIOLOGIC TREATMENTS**A. Hematopoietic Growth Factors**

- 35 Hematopoietic Growth Factors in Patients with Acute Leukemia **459**
Charles A. Schiffer
- 36 Hematopoietic Growth Factor Treatment in Leukemia **465**
Karl Welte

B. Immunotherapy

- 37 Immunotherapy of Leukemia **475**
Kenneth B. DeSantes and Paul M. Sondel
- 38 Therapy of Acute Leukemia with Monoclonal Antibodies and Immunoconjugates **485**
Eric L. Sievers, Dana C. Matthews, and Irwin D. Bernstein

PART VI: DRUG RESISTANCE

- 39 Drug Resistance in Acute Leukemias **497**
Jean-Piere Marie and Ollivier Legrand
- 40 Drug Resistance in Acute Leukemia **507**
Yaddanapudi Ravindranath and Robert J. Arceci

PART VII: MINIMAL RESIDUAL DISEASE

- 41 Minimal Residual Disease **527**
Dario Campana
- 42 Molecular Monitoring of Minimal Residual Disease **537**
Giovanni Cazzaniga and Andrea Biondi

- Index* **549**



<http://www.springer.com/978-0-89603-834-9>

Treatment of Acute Leukemias
New Directions for Clinical Research
Pui, C.-H. (Ed.)
2003, XVI, 562 p., Hardcover
ISBN: 978-0-89603-834-9
A product of Humana Press